All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub Steering Commitee met on May 5, 2022. The recorded discussion was chaired by Rena Buckstein, and featured Theo de Witte, Silvia Magalhães, and Yasushi Miyazaki. The topic of this discussion, “What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?”, was identified as an unmet educational need within MDS treatment.
What patient factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?
Buckstein begins by discussing two case studies, and the use of IPSS-R to define risk. De Witte talks about the effect that comorbidities can have on patient outcomes, and the committee discusses the treatment options and possible outcomes of the case study patients. Buckstein presents information on prognostic factors and the significance of mutations in prognosis. The committee also discusses how to calculate prognostic factors to decide treatment strategies, determine survival, and counsel patients. Buckstein then explains which genes are included in the IPSS-Molecular (IPSS-M) calculations. Finally, the committee discusses how the IPSS-M could be implemented in clinical settings, including potential problems.
Highlights of the 8th Translational Research Conference: Myelodysplastic Syndromes
The MDS Hub was pleased to speak to Theo de Witte, Radboudumc, Nijmegen, NL. We asked, What are the highlights of the ESH 8th Translational Research Conference:...
Practice-changing abstracts in myelodysplastic syndromes
World-leading experts in MDS shared the top abstracts from ASH 2020 that they believed could have the greatest impact on clinical practice.
Subscribe to get the best content related to MDS delivered to your inbox